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Abstract  
Despite advances in atopic dermatitis (AD) treatments, research into AD prevention has been 
slow.  Systematic reviews of prevention strategies promoting exclusive and prolonged 
breastfeeding, or interventions that reduce ingested or airborne allergens during pregnancy 
and after birth have generally not shown convincing benefit. Maternal/infant supplements 
such as Vitamin D have also not shown any benefit with the possible exception of omega-3 
fatty acids. Systematic reviews suggest that probiotics could reduce AD incidence by around 
20%, although the studies are quite variable and might benefit from individual patient data 
meta-analysis. Skin barrier enhancement from birth to prevent AD and food allergy has 
received recent interest, and results from national trials are awaited. It is possible that trying 
to influence major immunological changes that characterise AD at birth through infant-
directed interventions may be too late, and more attention might be directed at fetal 
programming in utero.  
 
 
Significance 
Just like we can prevent infectious diseases like polio, it should be possible to prevent eczema 
(atopic dermatitis), food allergy and asthma. Most things that have been tried so far to 
prevent eczema including exclusive breastfeeding, timing of starting solids, supplements like 
Vitamin D and reducing house dust mite don’t seem to work. Taking probiotics (friendly gut 
bacteria) during pregnancy probably reduces the risk of eczema by around 20%, although we 
are still not sure what combination is best. New research is trying to find out if special creams 
that make a baby’s skin barrier stronger can prevent eczema.   
Introduction and scope of this review 
Despite the familiar adage that “prevention is better than cure”, prevention of atopic 
dermatitis (AD) has been a relatively neglected topic of research until recently. A PubMed 
search (using the terms [atopic dermatitis OR eczema] AND treatment (August 14th 2019) 
revealed 19,755 hits, compared with just 3150 when disease terms were combined with 
“prevention”. Reasons for lack of research could include a lack of interest in population-
based research in favour of basic science (Figure 1), lack of research skill capacity in 
prevention research, lack of funding and a limited choice of identifiable risk factors that are 
amenable to public health manipulation. However, the number of AD prevention studies has 
increased over the last 10 years, especially in the field of probiotics and interventions to 
enhance the skin barrier. Basic science discoveries into the human microbiome and genetics 
of AD may have played a part in contributing to this recent trend.1,2 Whilst identifying risk 
factors that can be manipulated is an essential part of prevention research, understanding the 
mechanisms by which the effects of prevention are mediated is interesting but not essential. 
For example, the benefits of stopping smoking to prevent lung cancer became apparent from 
simple epidemiological research long before the mechanisms and precise carcinogens were 
discovere.3 Prevention of disease is arguably a much more logical and cost-effective way to 
manage the burden of a disease such as AD than focussing solely on drug treatment of sick 
individuals who seek medical help after a long chain of irreversible pathological events 
(Figure 2). Whilst some drugs such as penicillin for streptococcal infection can be curative, 
most only modify rather than cure chronic diseases like AD, they are often expensive, and all 
are associated with potential adverse effects.  
This article attempts to critically review the current state of science on the prevention of 
atopic dermatitis. Throughout this article, we will refer to the disease of interest as atopic 
dermatitis (AD), which is synonymous with atopic eczema or just “eczema”.4 We use the 
term atopic dermatitis to describe the clinical phenotype, rather than the scientific definition 
of clinical phenotype plus evidence of IgE sensitisation to environmental allergens. We start 
by introducing the reader to key considerations when designing or critically appraising 
studies of AD prevention, using our direct experience in designing and running a randomised 
controlled trial (RCT) of emollients to prevent AD. We then explore the main interventions 
that have been used to try and prevent AD such as maternal and infant dietary restrictions or 
supplements, aeroallergen avoidance and approaches designed to enhance the external skin 
barrier. The authors have chosen to use systematic reviews of evidence and RCTs as the 
evidence source where possible. Systematic reviews were harvested from the Centre of 
Evidence-Based Dermatology international collection of systematic reviews which is updated 
monthly by a senior information scientist (Dr. Douglas Grindlay).5 Rather than summarise all 
102 systematic reviews on AD prevention in this collection, we instead refer to overviews of 
systematic reviews or the most recent and comprehensive systematic reviews where possible. 
6,7 We used the Global Resource for Eczema Trials (GREAT) database for RCTs that might 
not yet be included in systematic reviews.8  
Some key basic considerations 
The power of prevention: Because prevention strategies act at a population level, their power 
is often not appreciated by individuals compared with treatments for a disease. Yet the power 
of prevention is potentially huge. In his article entitled “The power of prevention and what it 
requires” Woolf draws our attention to the fact that whereas new diabetes drugs that reduce 
glycohemoglobin levels by 0.5% often make the headlines, exercise, that can lower the 
incidence of diabetes by 50%, rarely achieves such publicity.9 The conquest of many 
infectious diseases such as diphtheria, smallpox, polio and measles are testament to the power 
of prevention, yet individuals who would have contracted these diseases are seldom 
“grateful” to those developing and implementing vaccines as it is unclear who would have 
contracted the disease in the first place. The recent re-emergence of measles due to misguided 
beliefs about vaccine safety, termed “vaccine hesitancy”, are timely reminders of the 
“invisible” and powerful effects of population-based interventions.10  
Primary, secondary and tertiary prevention; Primary prevention typically refers to intervening 
before health effects occur. Secondary prevention implies detecting a disease at an early stage 
to prevent worsening, whereas tertiary prevention is the reduction of symptoms or 
improvement in quality of life of those with established disease – i.e. where health care 
professionals normally operate.11 
Application of the PICO framework to AD prevention studies; PICO (Participant, 
Intervention, Comparator and Outcomes) is a framework used in evidence-based medicine to 
understand the structure of RCTs  and is useful when considering the design and critical 
appraisal of AD prevention trials.12  
Participants: Most AD prevention studies target a high risk population e.g. babies born to 
families with a first-degree relative with AD or associated allergic diseases such as asthma, 
hay-fever or food allergy. The advantage of this approach is that parents who have 
experienced AD themselves or witnessed it in family members are often highly motivated 
(during pregnancy or soon after) to undertake interventions that could prevent AD in their 
new baby. The disadvantage is that if the selected population is too narrow, the intervention 
may have a limited overall population impact. However, tackling an entire population such as 
all newborns is challenging, especially if the behaviour change modification is substantial, as 
parents will be less motivated to act on something that will be of little perceived benefit to 
their child. This phenomenon is known as the prevention paradox – a term coined by Rose to 
denote "a measure that brings large benefits to the community offers little to each 
participating individual”.13 Table 1 illustrates the possible trade-off between high and low 
risk approaches to AD prevention suggested previously.14 
Intervention: An essential step in the prevention of any disease is a thorough knowledge of 
risk factors that can be manipulated. For example, filaggrin gene mutations cannot be directly 
manipulated in utero at present (although it may be possible in time) whilst a reduction in 
house dust mite in the home environment is achievable. Another key consideration is the 
acceptability of interventions given that healthy people are being asked to undergo elaborate 
changes to their lives in order to prevent disease in a proportion of people – the identity 
whom will remain unknown to them. Here, there is often a trade-off between intensity of 
intervention which might achieve a larger effect (such as applying emollient twice a day to 
their child for 2 years, wash only in soft water and use no soap) versus those that are likely to 
have wider population reach (such as advice to use emollients once daily for the first year of 
life as in the BEEP trial).15 Testing acceptability of interventions is essential before 
proceeding to full scale evaluation.16 Assessing safety is paramount in prevention studies. 
Whilst individuals with severe AD might accept the risk of nausea and liver disease from 
methotrexate therapy, healthy individuals will have a low threshold for rejecting interventions 
with even small risks, such as the slipping on emollients spilt on a bathroom floor. 
Furthermore, minor adverse effects such as transient stinging after emollient application can 
reduce adherence to an intervention. 
Comparator: In the absence of a clear reference standard of an effective active treatment, 
control interventions for AD prevention trials are typically “standard care” (which is often 
not defined), an attention control, or some form of placebo (e.g. inactive probiotics). 
Convincing parents with a family history of AD to take part in a study with a 50:50 chance 
that their new baby will be allocated to the “no treatment” group can be challenging, and 
unless equipoise is carefully explained, parents may drop out if they don’t get the “new 
active” intervention. Feasibility studies that test randomisation and retention are essential and 
offer the opportunity to develop patient information materials with patients that imply active 
monitoring and altruistic rewards to overcome the notion of “control neglect” that can result 
in resentful demoralisation.17 
Outcomes: Whereas clinical trials of people with AD (prevalent cases) seek to reduce disease 
severity, one is trying to prevent new (incident) cases from developing in a prevention study. 
There is a lack of research on defining an incident case of AD. Simpson et al undertook a 
systematic review of definitions of an incident case of AD used in prevention studies.18 Of 
102 included studies, 27 did not define an incident case, 28 used the Hanifin-Rajka criteria, 
and 21 used definitions unique to that study without referencing the source. It is important to 
note that “chronic relapsing course” (a major criterion for the Hanifin-Rajka criteria), whilst 
acceptable for measuring cumulative incidence, is problematic when defining a new case 
which, by definition, has not yet become chronic. Yet diagnosing AD confidently in a baby 
on the first day they develop an eczematous rash is also fraught with problems as transient 
irritant eczematous dermatoses (which are probably not true AD) are common in infancy. 
Simpson et al suggested a compromise whereby the UK refinement of the Hanifin-Rajka 
criteria are used to denote a continuous or intermittent itchy skin condition lasting at least 4 
weeks.19   
Ideally outcome assessment should be separated from the intervention period by a clear 
margin to separate treatment effects from prevention effects. For example in the two small 
preliminary studies that suggested emollients might prevent AD, outcomes were assessed at 
the end of the intervention period, making it difficult to assess whether the apparent benefit 
was due to emollients preventing AD or actively treating new mild AD.16,20 This is why the 
main BEEP trial of emollients used during the first year is assessing the primary outcome of 
AD (those fulfilling the UK refinement of the Hanifin-Rajka criteria in the last year) at the 
age of 2 years.15 Whilst complete prevention of disease is the ultimate goal, prevention of 
more severe forms of the disease (which cause the most morbidity and result in most 
healthcare usage) is also an important goal in AD prevention trials. Because the shape of AD 
prevalence in any population is skewed to the left (Figure 3), even small shifts in the 
reduction of population severity can results in large gains in absolute terms for the number 
switching from severe to moderate or mild to very mild/subclinical disease. Time to onset of 
AD is another outcome that can be considered although it is debatable whether simply 
delaying onset of a miserable disease to an older age is really a bonus. Given that AD is 
closely related to other “atopic” diseases such as food allergy, asthma and hay fever, AD 
prevention studies also need to evaluate whether benefits are seen in these diseases too. 
Measuring other atopic diseases present their own challenges eg true food allergy has a low 
incidence making it unlikely that beneficial effects will be precisely measured even in large 
studies, and conditions like asthma have a later age of onset adding to the cost of following 
up individuals from RCTs that start at birth to older ages.   
Reducing bias: In addition to standard approaches to reduce RCT biases such as registration 
of study protocols before recruitment starts and ensuring randomisation is truly random and 
concealed, two biases require special consideration in AD prevention trials. The first is 
performance bias which results from treating intervention and control groups differently. 
More attention given to the intervention group can result in different ancillary behaviours that 
can affect AD risk, so it is important that both groups are treated in the same way in terms of 
regularity of contact and incentives from the research team, and any post-randomisation 
behaviours that could confound the study result are recorded. Sometimes such behaviours can 
include contamination of the intervention in the control group (because they think they are 
missing out on something beneficial), which can be a particular problem if the intervention is 
something that can be easily accessed by participants without the need for healthcare 
professionals, such as reduction of house dust mites in the home. Contamination should 
therefore be measured and explored in the analysis. A second challenge lies in the fact that 
because many interventions such as emollient application or installing a water softener cannot 
be blinded, it is essential to include some form of objective outcome assessment (eg visible 
eczema recorded by investigators blinded to intervention status) to mitigate the risk of 
information bias. Studies should present findings as absolute risk reductions as well as the 
more impressive sounding relative risk reductions in order to provide a more realistic 
indicator of population benefit. 
 
The evidence 
Primary prevention 
The 2011 overview of systematic reviews of primary prevention. 
In an attempt to reconcile the increasing number of Cochrane and non-Cochrane systematic 
reviews on AD prevention, a group (including the two authors) undertook an overview of all 
such systematic reviews in 2011 (search date up to August 2010). Quantitative and qualitative 
methods were used to collate and combine data where possible using Cochrane methods. 
Included reviews had to include some quantitative data that could be combined, search date 
within the last 5 years, and included participants between the ages of zero and 18 years. 
Seven systematic reviews containing 39 RCTs and 11,897 participants met the inclusion 
criteria. All seven reviews were considered methodologically sound, although the data from 
the review on probiotics had to be re-analysed as data from one trial had been included more 
than once in the same meta-analysis. Interventions included use of hydrolysed formula milk 
(extensive and partial), extended duration of exclusive breastfeeding, dietary supplementation 
with omega-3 and omega-6 oils, maternal dietary antigen avoidance during pregnancy, 
lactation or both, soy formula milks, along with prebiotics and probiotics. Participants were 
from a mixture of high and lower risk families, although risk was rarely adequately defined. 
None of the pooled interventions showed clear evidence of benefit for AD prevention. A 
subgroup analysis of those at high risk of developing AD based on just one RCT found that 
prebiotics (ingested substances that favour the growth of beneficial bacteria in the gut) 
decreased AD incidence by 58% (RR: 0.42; 95% CI: 0.21, 0.84) compared with no 
prebiotics. Data on whether those developing AD were truly atopic was missing from most of 
the studies, and in those that did, there was no evidence that the interventions decreased 
atopy. One non-randomised study suggested that prolonged exclusive breastfeeding (at least 6 
months) reduced AD incidence by 60% (RR 0.40, 95% CI 0.21 to 0.78). Despite the lack of 
any convincing signals for any of the interventions tested, the risk estimates for most 
interventions had low precision, indicating that some interventions with no evidence of 
benefit could still be useful. 
The post 2011 overview era 
INTERVENTIONS THAT ARE INGESTED BY MOTHERS AND/OR INFANTS: Also 
known as the “inside out” approach, ingested maternal/infant interventions include exclusive 
breastfeeding, delay or early introduction of foods other than milk, dietary restrictions, and 
dietary supplements. Although breastfeeding (exclusive or prolonged) has clear benefits for 
infants, a systematic review of 16 moderate quality observational studies suggests that it does 
not appear to be protective of AD.21 One large cluster RCT (the PROBIT trial in Belarus) that 
promoted breastfeeding found a reduction in self-reported flexural eczema but not lung 
function, a finding that needs to be replicated.22 Around a half of milk feeding studies have 
been judged to be at high risk of bias.23 A Cochrane review of five trials failed to show any 
benefit of maternal avoidance of allergenic foods for AD prevention.24 A 2019 systematic 
review of mainly observational studies of complementary feeding (whereby other foods and 
drinks complement human or formula milk) found no clear evidence between the age at 
which complementary feedings is started and the risk of AD, food allergy or asthma 
(moderate evidence).25 The same review found limited to strong evidence that introducing 
allergenic foods in year one of life to try and induce tolerance does not increase AD or food 
allergy risk, but may prevent egg and peanut allergy. The one well-conducted RCT included 
in the review found no benefit for AD prevention from early introduction of allergenic foods. 
26  
Interest in vitamin D supplementation as a possible preventative intervention stems from the 
association between low vitamin D levels and increased incidence and severity 
of AD. Vitamin D is also known to have a regulatory influence on skin barrier function and 
the immune system and skin barrier function, both of which are involved in AD 
development.27 A 2017 systematic review (search date January 2016) found 1 RCT and 3 
non-RCTs that addressed vitamin D supplementation in women and children as a means of 
preventing allergic diseases found no clear evidence of benefit but with low certainty of 
evidence.28 A more recent and well conducted RCT found no clear benefit of infant vitamin 
D supplementation in the primary prevention of AD.29 A systematic review of omega-3 long-
chain polyunsaturated fatty acids (such as from fish) intake during pregnancy found mixed 
results for AD prevention from observational studies, but a possible protective effect in the 
three included RCTs for early onset AD.30 
The evidence that ingested probiotics (non-pathogenic live bacteria or yeasts that can restore 
a dysfunctional pro-inflammatory gut microbiome) or prebiotics (non-digestible food 
ingredients that encourage beneficial bacteria to thrive) or both (synbiotics) can prevent AD 
is gathering momentum.31 The field is complicated as probiotics and prebiotics refer to a very 
wide range of ingredients, and they can be given to the mother during pregnancy, during 
lactation, to the infant after birth and various combinations of these and for different periods, 
leading to considerable heterogeneity which impacts on the ability to combine studies. One 
systematic review exploring the possible health benefits of yoghurt consumption among 
infants and toddlers that included two older cohort studies suggested a possible benefit for 
AD prevention, and called for new studies that evaluated such foods in a more contemporary 
setting.32 A systematic review in 2019 of 22 pooled trials published between January 2008 
and May 2018 showed a reduction in AD incidence (RR=0.81, 95%CI: 0.70-0.93) for those 
receiving probiotic supplementation during pregnancy and/or infancy. Subgroup analysis 
suggested that benefits were strongest for those receiving Lactobacillus and Bifidobacterium 
and for those in whom probiotic supplementation occurred during pregnancy and infancy and 
early rather than later AD.  Sources of study heterogeneity was also assessed and found to be 
mainly accounted by follow-up time (I2=62.7%) and length of probiotic supplementation 
(I2=53.5%). A more extensive systematic review that pooled 28 studies (27 good quality 
RCTs and 1 high quality cohort study, search date from inception to March 2018) showed a 
beneficial effect on AD prevention for probiotics compared with controls (OR 0.69; 95% CI 
0.58-0.82, Figure 4).33 Analysis of studies whereby probiotics were provided only prenatally 
or postnatally did not show such benefit, prompting the authors to conclude that benefits are 
only realised when probiotics are started during pregnancy and continued in the infant for the 
first 6 months of life. A broader and high quality systematic review of diet during pregnancy 
and infancy arrived at similar conclusions regarding a protective effect of probiotics on AD 
development from 19 probiotic trials (risk ratio 0.78; 95% CI 0.68-0.90; I2 = 61% and an 
absolute risk reduction of 44 cases per 1,000; 95% CI 20-64).23 Subgroup analysis suggested 
that it was maternal rather than infant probiotic supplementation that was important for 
realising a protective benefit. The evidence of prebiotics alone was weak due to high risk of 
bias, inconsistency, imprecision, and indirectness of study results. 
Although the World Allergy Organisation guideline panel has determined that there is a net 
benefit of probiotics for AD prevention, concerns regarding the heterogeneity of studies 
remains.34 A comprehensive review of probiotics across all human diseases concluded that 
the evidence for benefit in allergic diseases was still uncertain and a stimulus for further 
studies rather than firm clinical recommendations.35 A high quality individual patient data 
(IPD) meta-analysis - a type of systematic review that gathers and combines data belonging 
to individual patient who take part in clinical trials rather than aggregate data - would better 
identify who benefits most from probiotics, when and why.36 
INTERVENTIONS DIRECTED AT THE EXTERNAL SKIN SURFACE. The main 
“outside in” approaches for preventing AD, sensitisation and food allergy have included 
attempts to reduce airborne allergens such as house dust mite at the time of birth, increasing 
exposure to an anthroposophic environment and measures to enhance the skin barrier. A 
systematic review of house dust mite avoidance strategies (alone or with allergen avoidance) 
that included seven RCTs (search date October 2014) concluded such modalities do not 
decrease the risk of developing AD. Studies that have found strong associations between 
early exposures to anthroposophic environments such as farm animals have been limited to 
observational studies so far, but are a fruitful source of ideas for new possible primary 
interventions.37 Since the discovery of a strong association between AD and loss-of-function 
mutations in FLG, the gene encoding filaggrin – an essential protein for healthy skin barrier 
function, interest has increased on the potential benefits of skin barrier enhancement as a 
means of preventing AD and food allergy.38 Impaired skin barrier may precede eczema 
development and may be the route by which sensitisation to food allergens occurs.39,40 
Stimulated by the results of two small pilot RCTs that suggested a large benefit from using 
emollients on the skin of infants born to families with atopy, two large prevention RCTs have 
been set up to test the hypothesis that emollients from birth can prevent AD.15,16,20,41 The first 
of these studies (Barrier Enhancement for Eczema Prevention (BEEP) trial) is investigating 
daily emollient for the first year of life in babies born to atopic families. The second, the 
Preventing Atopic Dermatitis and Allergies in children study (PreventADALL), is a factorial 
trial - a trial whereby two or more interventions are carried out and assessed simultaneously. 
The PreventADALL trial compares (i) no intervention with (ii) skin care (oil‐bath at least 
5 days/week to age 9 months) and (iii) consecutive introduction of allergenic foods (peanut, 
milk, wheat, and egg) between 3 and 4 months of age and (iv) both skin and complementary 
feeding strategies. Results of BEEP and PreventADALL are not available at the time of 
writing. Two trials were published in 2019, both of which used complex emollients 
containing ingredients such as ceramide designed to enhance the skin barrier.42,43 The first 
study suggested that emollient therapy may reduce AD incidence, but this was not 
statistically significant, and there was no effect of emollient on barrier measurements.42 The 
second larger study was a factorial trial of emollient and synbiotics and found no evidence of 
a protective effect of either intervention.43 At least 10 other similar prevention trials that 
explore the potential of different skin barrier products to prevent AD in high and low risk 
populations.44 Together, most of these studies now form part of a prospectively-planned 
meta-analysis consortium called SCiPAD (Skin care intervention for prevention of atopic 
disease).45,46 Other direct to skin approaches such as “probiotic creams” that serve to 
influence the early skin microbiome towards one that is less favourable for the development 
of AD are also worthy of further research.47 
COMBINED APPROACHES. Whilst it might be easier to implement one simple 
intervention to prevent AD, it might be possible to combine multiple interventions each of 
which has a small beneficial effect, especially if they interact to produce more than the sum 
of the whole. The hazard of a “throw in everything that might work” strategy is that they can 
become black boxes that are not amenable to replication, unless the components are separated 
using designs such as factorial trials as currently being done in the PreventADALL study.48 
 
Secondary prevention Treating AD more aggressively when it first appears in an attempt to 
alter the subsequent course of disease in terms of remission or decreasing severity is an 
attractive notion. One such study of aggressive early treatment is underway in Japan, in 
which 650 infants who develop AD between the ages of 7-13 weeks old will be randomly 
assigned to enhanced topical anti-inflammatory treatment or conventional treatment with the 
aim of preventing food allergy and reducing AD severity.49 Poorly controlled disease 
resulting in skin damage from scratching can lead to a cascade that results in individuals 
developing autoimmunity towards their own skin components, a phenomenon that might be 
key to driving disease chronicity.50 Other non-pharmacological approaches such as 
behavioural methods to limit skin damage from scratching when AD first appears are also 
worth considering in this context.51 Like primary prevention, secondary prevention should 
not be taken lightly, especially with regards to safety. If for example, only 10% of those 
given early aggressive treatment with prolonged topical corticosteroids benefit from such 
therapy, then 90% arguably undergo “overtreatment” and incur side effects in order to benefit 
the few. 
So far, prevention of related diseases such as food allergy and asthma have only been 
considered in the context of early interventions that primarily aim to prevent AD, but another 
important question to consider in relation to secondary prevention of AD is whether 
interventions that are initiated when AD is first identified can prevent the development of 
conditions such as asthma. Such a concept was the basis of the Early Treatment of the Atopic 
Child study (ETAC) whereby 795 children with new onset AD between 1 and 2 years of age 
were randomised to cetirizine or placebo for 18 months. Cetirizine was chosen because it 
might inhibit eosinophil tracking to the lungs as well as its anti-histamine effect. The ETAC 
study did not show that asthma could be prevented by such an approach.52 Although urticaria 
rates were less in the intervention group, severity of AD was not reduced in the cetirizine 
group either, throwing doubt on the value of anti-histamines in the treatment of AD – an 
observation that has been confirmed in a subsequent Cochrane review.53,54 A follow up RCT 
from ETAC called the EPAAC study explored the use of levocetirizine for the prevention of 
asthma in children with AD who were sensitised to grass and/or house dust mite was stopped 
due to lack of benefit.55 
Tertiary prevention. In its broadest sense tertiary prevention refers to disease treatment, 
prevention of deterioration, disease complications and sequelae. In relation to AD, one of the 
most important advances in disease treatment over the last 30 years has been the concept of 
proactive treatment (two consecutive days per week) for those who have been stabilised has 
been shown to dramatically reduce the number of subsequent flares.56 A meta-analysis by 
Schmitt et al showed that topical fluticasone reduced the risk of further flares by around half 
(relative risk 0·46, 95% CI 0·38-0·55) with more modest reductions in flares with weekly 
topical tacrolimus (RR 0·78, 95% CI 0·60-1·00).57 When considering prevention of flares, it 
is equally important to consider induction of remission before proactive therapy is initiated – 
the concept of “get control then keep control” as illustrated schematically in Figure 5.58 
Another review suggested that Vitamin D supplementation for early disease may have a small 
beneficial effect in reducing later disease severity.59 Given that AD is a chronic relapsing 
condition, prevention of flares and embracing the concept of overall disease control have 
become key considerations in improving quality of life of AD sufferers.60 Better prediction of 
flares in what often appears a random process offers exciting prospects for personalised 
medicine. 
What about adult-onset atopic dermatitis?  Most of the evidence discussed relates to early 
life. This is with good reason as AD typically starts in the first few years of life. Recent 
studies have drawn attention to the importance of AD in adults, pointing out that around 1 in 
4 of those with adult AD appear to develop it for the first time in adulthood.61 Less is known 
about the risk factors for adult-onset AD in order to identify candidates for prevention 
studies.62 One study of 67,643 US women postulated that niacin intake might protect against 
adult AD since niacin has been found to decrease transepidermal water loss. Instead, it found 
that adult AD was paradoxically increased with niacin intake, a finding that needs to be 
replicated.63 
 
Conclusions 
The last few decades of research into the prevention of AD have thrown up very few signals 
of simple, safe interventions that are likely to be effective at a population level. Errors in the 
design and reporting of studies tend to be repeated rather than learned, and the same old 
interventions are often tested again and again with little new insight. Past research has also 
been concerned with a rather fruitless obsession with allergic factors despite the fact that 
around half of people with “atopic” dermatitis are not atopic in the scientific sense.64 The 
main exception to the lack of positive findings for AD prevention has been the use of 
probiotics. Probiotic use has consistently shown modest benefit and good safety when tested 
in different populations around the world, prompting the World Allergy Organisation 
guideline panel to determine that there is a likely net benefit from using probiotics resulting 
primarily from prevention of eczema. The WAO guideline panel suggests using probiotics in: 
a) pregnant women at high risk of having an allergic child; b) women who are breastfeeding 
infants at high risk of developing allergy; and c) infants at high risk of developing allergy. 
New evidence is likely to emerge on barrier enhancement as a strategy for AD prevention 
over the next 5 years, especially through the SCiPAD prospectively planned meta-analysis. 
In terms of future research, it is worth exploring new risk factors rather than doing more 
studies on the same interventions that do not look promising. The comprehensive overview of 
systematic reviews of epidemiology of allergic diseases conducted by Genuniet et al is a 
good place to start and by reconsidering the host of non-specific, specific and internal factors 
that make up the “exposome” for AD. 65,66 Rather than considering reduction of harmful 
exposures, exploration of increasing potentially beneficial substances might be considered. 
Given the inverse relationship between helminth exposure and allergic sensitisation, 
derivative products that switch off the dysfunctional immune response could be explored 
further.67 The fetal environment may be a better place to focus than the infant environment. 
Rather than conducting more probiotic trials, stopping and conducting a more refined 
analysis of the 28 or so existing studies using individual patient data meta-analysis may help 
to bridge the gap between cautious recommendation and implementation in order to benefit 
future generations of children who might otherwise be destined to a life with AD. 
  
Figures and table legends 
 
Figure 1. Research into atopic dermatitis over the last 50 years has been dominated by 
interest in cells rather than broader questions such as whether disease prevention is possible 
Figure 2: Although the concept of prevention of atopic dermatitis is rarely discussed at 
international meetings, an upstream approach is a far more logical approach to reduce the 
burden of disease at a population level than the current approach of treating sick individuals 
with expensive drugs who present to secondary care after a long chain of pathological events. 
Figure 3: Even if atopic dermatitis cannot be prevented completely, shifting the population 
severity distribution of disease to the left could have a huge impact on pushing more into 
subclinical disease and reducing the proportion with severe disease who suffer the most and 
who consume most health resources 
Figure 4: Forest plot depicting a meta-analysis that used a random effects model combining 
28 studies that evaluated the preventive effect of probiotics to prevent atopic dermatitis. 
Although the summary odds ratio suggests clear benefit (odds ratio of 0.69; 95% CI 0.58–
0.82; P < 0.0001), there was considerable heterogeneity between the studies (I2 = 53.6%). 
Reproduced with kind permission from the American Journal of Clinical Dermatology. 
Figure 5: A more subtle interpretation of tertiary prevention is the principle of inducing 
remission of atopic dermatitis with an initial blast of topical treatment followed by prevention 
of disease flares with weekly pulses of two consecutive days of topical treatment (also known 
as the Centre of Evidence-Based Dermatology “get control and keep control” approach). 
When contrasted against more traditional reactive approaches, the proactive approach results 
in more disease being pushed into a subclinical state and hence better overall disease control. 
Reproduced with kind permission from the Journal of Allergy and Clinical Immunology. 
Table: Hypothetical example of the prevention yield from a high risk vs low risk prevention 
approach for atopic dermatitis, depicting an average Western population where 40% of 1000 
adult couples with a strong family history of atopy and 60% do not. If 30% of the high risk 
babies develop AD compared with 15% without such a family history, a high risk approach 
would only prevent 57% (120/120+90) of AD cases at a population level. Adapted from 
Williams HC. Atopic Dermatitis. In: Williams HC, Strachan DP (eds). The Challenge of 
Dermato-Epidemiology. Boca Raton, CRC Press Inc., 1997. 
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Although the summary odds ratio suggests clear benefit (odds ratio of 0.69; 95% CI 0.58–
0.82; P < 0.0001), there was considerable heterogeneity between the studies (I2 = 53.6%)33. 
Reproduced with kind permission from the American Journal of Clinical Dermatology. 
 
 
  
  
Figure 5: A more subtle interpretation of tertiary prevention is the principle of inducing 
remission of atopic dermatitis with an initial blast of topical treatment followed by prevention 
of disease flares with weekly pulses of two consecutive days of topical treatment (also known 
as the Centre of Evidence-Based Dermatology “get control and keep control” approach). 
When contrasted against more traditional reactive approaches, the proactive approach results 
in more disease being pushed into a subclinical state and hence better overall disease control. 
Reproduced with kind permission from the Journal of Allergy and Clinical Immunology. 
 
  
    1000 adult couples 
 
400 “high risk” couples    600 “low risk” couples 
 
Who give birth 400 high risk babies  Who give birth to 600 low risk babies 
 
120 (30% of 400) develop AD  90 (15% of 600) develop AD 
 
Table 1: Hypothetical example of the prevention yield from a high risk vs low risk 
prevention approach for atopic dermatitis, depicting an average Western population where 
40% of 1000 adult couples with a strong family history of atopy and 60% do not. If 30% of 
the high risk babies develop AD compared with 15% without such a family history, a high 
risk approach would only prevent 57% (120/120+90) of AD cases at a population level. 
Adapted from Williams HC. Atopic Dermatitis. In: Williams HC, Strachan DP (eds). The 
Challenge of Dermato-Epidemiology. Boca Raton, CRC Press Inc., 1997. 
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